{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:06:48Z","timestamp":1793200008776,"version":"4.5.0"},"reference-count":93,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"DFG","award":["329628492"],"award-info":[{"award-number":["329628492"]}]},{"name":"DFG","award":["515356385"],"award-info":[{"award-number":["515356385"]}]},{"name":"DFG","award":["MA 4115\/1-2\/3"],"award-info":[{"award-number":["MA 4115\/1-2\/3"]}]},{"name":"DFG","award":["SFB1321"],"award-info":[{"award-number":["SFB1321"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>IgG4 antibodies exhibit unique structural and functional properties, which distinguish them from other IgG subclasses. Among clinicians, IgG4 has been primarily associated with IgG4-related diseases (IgG4-RDs), such as autoimmune pancreatitis, where its role has been a focus of intense discussion. However, growing evidence reveals that IgG4 is involved in a broader spectrum of immune-regulatory processes, extending beyond IgG4-RDs and positioning it as a key modulator of immune tolerance. In this context, several specific features allow IgG4 to play dual roles, serving as a protective factor in immune regulatory settings, such as allergic responses and antibody therapies that require tolerance induction towards target cells, while its role in IgG4-RDs remains uncertain, potentially contributing to disease or mitigating tissue damage. This review examines the pathophysiological roles of IgG4 in the regulation of immune responses, highlighting its involvement in both homoeostasis and disease. Furthermore, it explores the therapeutic potential of harnessing IgG4\u2019s unique features, not only for IgG4-associated diseases, but also for other indications, where promoting beneficial IgG4 responses could offer therapeutic advantages.<\/jats:p>","DOI":"10.1136\/gutjnl-2025-335375","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:20:22Z","timestamp":1751376022000},"page":"1528-1538","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications"],"prefix":"10.1136","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8331-9778","authenticated-orcid":false,"given":"Ignazio","family":"Piseddu","sequence":"first","affiliation":[{"name":"Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany"},{"name":"Bavarian Center for Cancer Research (BZKF), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-6459","authenticated-orcid":false,"given":"Julia","family":"Mayerle","sequence":"additional","affiliation":[{"name":"Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany"},{"name":"Bavarian Center for Cancer Research (BZKF), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal Mukund","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany"},{"name":"Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F R","family":"Boehmer","sequence":"additional","affiliation":[{"name":"Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany"},{"name":"Bavarian Center for Cancer Research (BZKF), Munich, Germany"},{"name":"Boston Children\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026073008001264000_74.9.1528.1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.106"},{"key":"2026073008001264000_74.9.1528.2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"2026073008001264000_74.9.1528.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.046"},{"key":"2026073008001264000_74.9.1528.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00871-z"},{"key":"2026073008001264000_74.9.1528.5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1584322"},{"key":"2026073008001264000_74.9.1528.6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050219-034449"},{"key":"2026073008001264000_74.9.1528.7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032909","article-title":"The clinical significance of allergen-specific IgG4 in allergic diseases","volume":"13","author":"Qin","year":"2022","journal-title":"Front Immunol"},{"key":"2026073008001264000_74.9.1528.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.9.3941"},{"key":"2026073008001264000_74.9.1528.9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"2026073008001264000_74.9.1528.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"2026073008001264000_74.9.1528.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y"},{"key":"2026073008001264000_74.9.1528.12","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-015-0580-7","article-title":"IgG4 Characteristics and Functions in Cancer Immunity","volume":"16","author":"Crescioli","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026073008001264000_74.9.1528.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144603"},{"key":"2026073008001264000_74.9.1528.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.0019-2805.2001.01341.x"},{"key":"2026073008001264000_74.9.1528.15","doi-asserted-by":"publisher","DOI":"10.1021\/ja203638y"},{"key":"2026073008001264000_74.9.1528.16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.036"},{"key":"2026073008001264000_74.9.1528.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.049"},{"key":"2026073008001264000_74.9.1528.18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.2.661"},{"key":"2026073008001264000_74.9.1528.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248943"},{"key":"2026073008001264000_74.9.1528.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754"},{"key":"2026073008001264000_74.9.1528.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01544-8"},{"key":"2026073008001264000_74.9.1528.22","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14512"},{"key":"2026073008001264000_74.9.1528.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00690-x"},{"key":"2026073008001264000_74.9.1528.24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00732.x"},{"key":"2026073008001264000_74.9.1528.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.044"},{"key":"2026073008001264000_74.9.1528.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.4718"},{"key":"2026073008001264000_74.9.1528.27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830190724"},{"key":"2026073008001264000_74.9.1528.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3730"},{"key":"2026073008001264000_74.9.1528.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003336"},{"key":"2026073008001264000_74.9.1528.30","doi-asserted-by":"publisher","DOI":"10.1111\/all.15031"},{"key":"2026073008001264000_74.9.1528.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279389","article-title":"Increased number of T cells and exacerbated inflammatory pathophysiology in a human IgG4 knock-in MRL\/lpr mouse model","volume":"18","author":"Gon","year":"2023","journal-title":"PLoS One"},{"key":"2026073008001264000_74.9.1528.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200090"},{"key":"2026073008001264000_74.9.1528.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.02.017"},{"key":"2026073008001264000_74.9.1528.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.12.1088"},{"key":"2026073008001264000_74.9.1528.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04168-4"},{"key":"2026073008001264000_74.9.1528.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.130.2.722"},{"key":"2026073008001264000_74.9.1528.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.012"},{"key":"2026073008001264000_74.9.1528.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-022-00531-w"},{"key":"2026073008001264000_74.9.1528.39","doi-asserted-by":"publisher","DOI":"10.1179\/136485910X12786389891407"},{"key":"2026073008001264000_74.9.1528.40","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12001"},{"key":"2026073008001264000_74.9.1528.41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.12.4298"},{"key":"2026073008001264000_74.9.1528.42","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/58.2.189"},{"key":"2026073008001264000_74.9.1528.43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65579"},{"key":"2026073008001264000_74.9.1528.44","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1032492","article-title":"Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma","volume":"4","author":"Karagiannis","year":"2015","journal-title":"Oncoimmunology"},{"key":"2026073008001264000_74.9.1528.45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25627"},{"key":"2026073008001264000_74.9.1528.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.03.001"},{"key":"2026073008001264000_74.9.1528.47","doi-asserted-by":"publisher","DOI":"10.5858\/2008-132-48-SIGFLI"},{"key":"2026073008001264000_74.9.1528.48","doi-asserted-by":"crossref","unstructured":"de Monte L , Clemente F , Ruggiero E , et al . Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE. EBioMedicine 2023. doi:10.1016\/j.ebiom.2023.104819","DOI":"10.1016\/j.ebiom.2023.104819"},{"key":"2026073008001264000_74.9.1528.49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1091098"},{"key":"2026073008001264000_74.9.1528.50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000661","article-title":"An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026073008001264000_74.9.1528.51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1880687","article-title":"IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer","volume":"10","author":"Jordakieva","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026073008001264000_74.9.1528.52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009034","article-title":"Fc\u2013Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies","volume":"12","author":"Zhang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026073008001264000_74.9.1528.53","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0837"},{"key":"2026073008001264000_74.9.1528.54","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620934911"},{"key":"2026073008001264000_74.9.1528.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102646"},{"key":"2026073008001264000_74.9.1528.56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216561"},{"key":"2026073008001264000_74.9.1528.57","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310336"},{"key":"2026073008001264000_74.9.1528.58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605"},{"key":"2026073008001264000_74.9.1528.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409712"},{"key":"2026073008001264000_74.9.1528.60","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.141"},{"key":"2026073008001264000_74.9.1528.61","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314548"},{"key":"2026073008001264000_74.9.1528.62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq0997","article-title":"Laminin 511 is a target antigen in autoimmune pancreatitis","volume":"10","author":"Shiokawa","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026073008001264000_74.9.1528.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.009"},{"key":"2026073008001264000_74.9.1528.64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101015","article-title":"Laminin 511-E8, an autoantigen in IgG4-related cholangitis, contributes to cholangiocyte protection","volume":"6","author":"Trampert","year":"2024","journal-title":"JHEP Rep"},{"key":"2026073008001264000_74.9.1528.65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1272084","article-title":"IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease","volume":"15","author":"Motta","year":"2024","journal-title":"Front Immunol"},{"key":"2026073008001264000_74.9.1528.66","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"The Lancet"},{"key":"2026073008001264000_74.9.1528.67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738540"},{"key":"2026073008001264000_74.9.1528.68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb00727.x"},{"key":"2026073008001264000_74.9.1528.69","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26999"},{"key":"2026073008001264000_74.9.1528.70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216368"},{"key":"2026073008001264000_74.9.1528.71","doi-asserted-by":"publisher","DOI":"10.1002\/art.27435"},{"key":"2026073008001264000_74.9.1528.72","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-201694","article-title":"Relapse patterns in IgG4-related disease","volume":"71","author":"Yamamoto","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026073008001264000_74.9.1528.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.01.018"},{"key":"2026073008001264000_74.9.1528.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.026"},{"key":"2026073008001264000_74.9.1528.75","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.02.026"},{"key":"2026073008001264000_74.9.1528.76","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg7327","article-title":"Is it bad, is it good, or is IgG4 just misunderstood?","volume":"8","author":"Pillai","year":"2023","journal-title":"Sci Immunol"},{"key":"2026073008001264000_74.9.1528.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"2026073008001264000_74.9.1528.78","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"The Lancet"},{"key":"2026073008001264000_74.9.1528.79","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.08.038"},{"key":"2026073008001264000_74.9.1528.80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02140","article-title":"Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells","volume":"9","author":"Juli\u00e1","year":"2018","journal-title":"Front Immunol"},{"key":"2026073008001264000_74.9.1528.81","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00876-4"},{"key":"2026073008001264000_74.9.1528.82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417320112"},{"key":"2026073008001264000_74.9.1528.83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579"},{"key":"2026073008001264000_74.9.1528.84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0762"},{"key":"2026073008001264000_74.9.1528.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2012.06.012"},{"key":"2026073008001264000_74.9.1528.86","doi-asserted-by":"crossref","unstructured":"Huang Z , Pang X , Zhong T , et al . Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.924542","DOI":"10.3389\/fimmu.2022.924542"},{"key":"2026073008001264000_74.9.1528.87","doi-asserted-by":"crossref","first-page":"x24","DOI":"10.1093\/annonc\/mdy487.042","article-title":"A phase Ia\/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors","volume":"29","author":"Deva","year":"2018","journal-title":"Ann Oncol"},{"key":"2026073008001264000_74.9.1528.88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003735","article-title":"Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments","volume":"10","author":"Moreno-Vicente","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026073008001264000_74.9.1528.89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1172969"},{"key":"2026073008001264000_74.9.1528.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.01.003"},{"key":"2026073008001264000_74.9.1528.91","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06797-9"},{"key":"2026073008001264000_74.9.1528.92","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2836-1"},{"key":"2026073008001264000_74.9.1528.93","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07962-4"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-335375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:37:55Z","timestamp":1785436675000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-335375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":93,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/gutjnl-2025-335375"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-335375","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}